Objectives
To assess the effect of palliative care interventions in advanced dementia and to report on the range of outcome measures used.
Search methods
We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group's Specialized Register on 4 February 2016. ALOIS contains records of clinical trials identified from monthly searches of several major healthcare databases, trial registries and grey literature sources. We ran additional searches across MEDLINE (OvidSP), Embase (OvidSP), PsycINFO (OvidSP), CINAHL (EBSCOhost), LILACS (BIREME), Web of Science Core Collection (ISI Web of Science), ClinicalTrials.gov and the World Health Organization ICTRP trial portal to ensure that the searches were as comprehensive and as up-to-date as possible.
Selection criteria
We searched for randomised (RCT) and non-randomised controlled trials (nRCT), controlled before-and-after studies (CBA) and interrupted time series studies evaluating the impact of palliative care interventions for adults with dementia of any type, staged as advanced dementia by a recognised and validated tool. Participants could be people with advanced dementia, their family members, clinicians or paid care staff. We included clinical interventions and non-clinical interventions. Comparators were usual care or another palliative care intervention. We did not exclude studies on the basis of outcomes measured and recorded all outcomes measured in included studies.
Main results
We identified two studies of palliative care interventions for people with advanced dementia. We did not pool data due to the heterogeneity between the two trials in terms of the interventions and the settings. The two studies measured 31 different outcomes, yet they did not measure the same outcome. There are six ongoing studies that we expect to include in future versions of this review.
Both studies were at high risk of bias, in part because blinding was not possible. This and small sample sizes meant that the overall certainty of all the evidence was very low.
One individually randomised RCT (99 participants) evaluated the effect of a palliative care team for people with advanced dementia hospitalised for an acute illness. While this trial reported that a palliative care plan was more likely to be developed for participants in the intervention group (risk ratio (RR) 5.84, 95% confidence interval (CI) 1.37 to 25.02), the plan was only adopted for two participants, both in the intervention group, while in hospital. The palliative care plan was more likely to be available on discharge in the intervention group (RR 4.50, 95% CI 1.03 to 19.75). We found no evidence that the intervention affected mortality in hospital (RR 1.06, 95% CI 0.53 to 2.13), decisions to forgo cardiopulmonary resuscitation in hospital or the clinical care provided during hospital admission, but for the latter, event rates were low and the results were associated with a lot of uncertainty.
One cluster RCT (256 participants, each enrolled with a family carer) evaluated the effect of a decision aid on end-of-life feeding options on surrogate decision-makers of nursing home residents with advanced dementia. Data for 90 participants (35% of the original study) met the definition of advanced dementia for this review and were re-analysed for the purposes of the review. In this subset, intervention surrogates had lower scores for decisional conflict measured on the Decisional Conflict Scale (mean difference -0.30, 95% CI -0.61 to 0.01, reduction of 0.3 to 0.4 units considered meaningful) and were more likely than participants in the control group to discuss feeding options with a clinician (RR 1.57, 95% CI 0.93 to 2.64), but imprecision meant that there was significant uncertainty about both results.
Authors' conclusions
Very little high quality work has been completed exploring palliative care interventions in advanced dementia. There were only two included studies in this review, with variation in the interventions and in the settings that made it impossible to conduct a meta-analysis of data for any outcome. Thus, we conclude that there is insufficient evidence to assess the effect of palliative care interventions in advanced dementia. The fact that there are six ongoing studies at the time of this review indicates an increased interest in this area by researchers, which is welcome and needed.
P L A I N L A N G U A G E S U M M A R Y

Palliative care for people with advanced dementia
Review question
In this research, we wanted to see if palliative care helps people with advanced dementia or helps their family or carers. We also wanted to describe how researchers tried to measure the effect of palliative care.
Background
People with advanced dementia have serious memory problems and have problems making simple decisions. They are usually no longer able to communicate by talking. They need a lot of help from their carers. People with advanced dementia can live for a long time. It is very hard to say exactly how long a person with advanced dementia will live.
Palliative care (or end-of-life care) is a particular way of caring for people who have diseases that cannot be cured. The main aims of palliative care are to reduce pain and to maintain the best possible quality of life as death approaches. Palliative care is used a lot with people with cancer but is not used much for people with advanced dementia. 
Study characteristics
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
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B A C K G R O U N D Description of the condition
Description of the intervention
In this review, we included and appraised interventions aimed at improving palliative care delivered to people with advanced dementia. An intervention can impact one or more of the following domains:
• the person with dementia, focusing on managing pain or on psychological, social or spiritual dimensions of the person with dementia;
• the family/carer, with an emphasis on carer well-being, carer burden and bereavement support;
• the quality of care, which may include interventions such as advance care planning, staff education programmes or the organisation and delivery of care;
• the interventions may focus on individual components of care, for example, pain management, or they may be multicomponent interventions aimed at changing the way care is delivered and at improving communication between clinicians, professional carers, the person with dementia and the family.
How the intervention might work
There is some evidence of the benefits of palliative care teams, mainly for people with cancer (Higginson 2003; Gomes 2013), but evidence on the effects of other palliative care interventions is inconclusive (Candy 2012; Chan 2016). Given the complexity of managing people with advanced dementia in the terminal stages of their disease, we anticipated that several different types of interventions could work to improve care in advanced dementia. It is likely that the mechanism by which the interventions may work will also vary significantly, for example:
• for the person with advanced dementia: by providing relief from pain, avoiding unnecessary investigations, medications and transitions, and by increasing comfort;
• for the family: by increasing their understanding of what to expect during the dying process, by maximising communication with healthcare professionals, by helping families cope with the illness and bereavement, and by reducing the care burden on family carers;
• on the organisation of care: by placing the person with advanced dementia at the centre of the care process, by raising the level of awareness of the needs of the person with advanced dementia and by enhancing the communication skills of professional carers.
Why it is important to do this review
There is an increased focus worldwide on extending palliative care to all those in need of it, as evidenced by the 2014 white paper from the EAPC defining optimal palliative care for people with dementia (van der Steen 2014). There is a need to synthesise the evidence available on interventions that improve care for people with advanced dementia for policy makers and clinicians. The chronic disease course of dementia gives families, carers, clinicians and, during the early stages of the disease, the person with dementia, the opportunity to look ahead and plan for the final stages of care. Such decisions should be underpinned by good-quality evidence. There is potential for some overlap between this review and the Cochrane Review completed by Hall 2011 entitled Interventions for improving palliative care for older people living in nursing care homes. However, our review differs from Hall 2011 in that it focuses on people with advanced dementia in need of palliative care, living in any setting and includes both interventions that focus on individual components of palliative care, for example, pain management, and multi-component service interventions.
O B J E C T I V E S
M E T H O D S
Criteria for considering studies for this review
Types of studies
Because of the complexity of conducting randomised controlled trials (RCTs) with people with advanced dementia, we anticipated few RCTs. Therefore, we considered it necessary to include a broader range of controlled comparison studies, to help us to determine the effect of interventions to improve care in advanced dementia. Therefore, we considered RCTs, trials where allocation was truly random (e.g. random number table); non-randomised controlled trials (nRCTs), where allocation was not truly random (e.g. alternation), controlled before-and-after studies (CBA) and interrupted time series (ITS) studies for inclusion in this review. We used the criteria defined in the Cochrane Effective Practice and Organisation of Care (EPOC) Review Group guidelines (EPOC 2013) for inclusion of CBA and ITS studies, as follows:
• CBA studies must have had at least two intervention sites and two control sites;
• ITS studies must have had a clearly defined point in time when the intervention occurred and at least three data points before and three after the intervention.
Types of participants
Adults of either gender, with dementia of any type staged as advanced by a recognised and validated tool, such as stage 6d or above on the FAST (Reisberg 1988), CDR-3 (Severe) on the Clinical Dementia Rating (CDR) Scale (Hughes 1982), stage 7 on the Global Deterioration Scale (GDS) (Reisberg 1982), or any other validated measure. We also included studies where the participants were informal or paid carers of people with advanced dementia. We anticipated that there would be few studies where all participants had advanced dementia. Therefore, we decided a priori to include studies where separate results for people with advanced dementia were available or where more than 80% of the study population had advanced dementia, as defined above. Participants could be living in their own homes or with a family member, in supported housing, in any type of long-term care facility, in a hospice or in hospital.
Types of interventions
We included clinical and non-clinical interventions including one or more of the following:
• assessment and management of physical, psychological and spiritual symptoms of the person;
• advance care planning, including decision-aid interventions for family carers/surrogates;
• management of transition(s) of the person with advanced dementia from one care setting to another;
• education and training on living and dying with advanced dementia for family members;
• education and training on advanced dementia for clinicians and professional care staff;
• changes in the organisation of care to incorporate a palliative approach to care for the person with advanced dementia.
Comparison
We prespecified the following comparisons:
• palliative care interventions versus usual care or optimised usual care;
• palliative care intervention versus another palliative care intervention.
Types of outcome measures Primary outcomes
• Improvement of care. We anticipated that many different outcomes would have been measured in studies included in this review, using many different measurement scales. Therefore, we reported on all outcomes used in the included studies and aimed to categorise them using the "domains and dimensions of outcome measures in palliative care" (Bausewein 2011). We planned to analyse separately outcomes for the person with advanced dementia, outcomes related to the family or carer, and outcomes related to the quality of care. We looked for outcomes covering both beneficial effects and adverse events. We did not exclude studies on the basis of the outcomes measured.
Search methods for identification of studies Electronic searches
We searched ALOIS (www.medicine.ox.ac.uk/alois), the Cochrane Dementia and Cognitive Improvement Group Specialized Register. The search terms were: palliative OR "end of life" OR dying. The Information Specialists of the Cochrane Dementia and Cognitive Improvement Group maintain ALOIS, which contains dementia and cognitive improvement studies identified from:
• monthly searches of several major healthcare databases: MEDLINE; Embase; CINAHL; PsycINFO and LILACS;
• monthly searches of several trial registers: metaRegister of Controlled Trials; Umin Japan Trial Register and World Health Organization (WHO) portal (which covers ClinicalTrials.gov; ISRCTN; Chinese Clinical Trials Register; German Clinical Trials Register; Iranian Registry of Clinical Trials and the Netherlands National Trials Register, plus others);
• quarterly search of the Cochrane Library's Central Register of Controlled Trials (CENTRAL);
• monthly searches of several grey literature sources: ISI Web of knowledge Conference Proceedings; Index to Theses and Australasian Digital Theses.
To view a list of all sources searched for ALOIS see About ALOIS on the ALOIS website. In addition, we performed separate searches to ensure we retrieve the most up-to-date results. The search strategies run are in Appendix 1.
Data collection and analysis
We developed the methods used in this Cochrane Review in accordance with recommendations described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
Selection of studies
After merging search results and discarding duplicates, two review authors (EM, SC) independently screened the titles and abstracts of all identified citations to identify potential studies. We classified the citations into three groups: 'exclude', 'potentially relevant' or 'unsure'. We excluded papers classified by both review authors as 'exclude'. We retrieved the full-text versions of all 'potentially relevant' and 'unsure' citations for definitive assessment of eligibility. We obtained sufficient translations of non-English citations to allow us to judge whether to include or exclude the studies. For conference abstracts, we searched for related publications, and, when unable to find any, we contacted the study authors to see whether any further unpublished data were available. Two review authors (EM, SC) independently screened the full texts for a comprehensive assessment against the inclusion criteria. We resolved any disagreements through discussion, and when required, we consulted with all the review team. We used EndNote software to manage citations.
Data extraction and management
We designed and tested a data extraction form. Where possible, we obtained the following information for each included study:
• data on the inclusion criteria for the original intervention (study design; setting, including the country; details on the place of residence of participants; types of participants; type of intervention; type of comparator, outcomes measured);
• number of participants eligible, number randomised and reasons for not including eligible participants in the study, including both the person with dementia and carers;
• length of follow-up, number of follow-up points;
• participant characteristics, including details on diagnosis, how severity was staged and, where appropriate, details of comorbidity/comorbidities;
• carer/family member characteristics, including involvement in delivering care to the person with advanced dementia;
• details about the intervention (components, length, mode of delivery, materials given to participants, providers, level of contact with family, etc.), comparison (including definition of usual care);
• data to assess the risk of bias of the original trial (randomisation; blinding of participants and personnel; description of dropouts, withdrawals and missing data; details on possible contamination between control and intervention groups; and selective outcome reporting);
• baseline and end of intervention data on outcomes of interest for the review, scales used to measure outcomes.
Two review authors (EM, SC) extracted data using the agreed form and resolved discrepancies through discussion. We had planned to consult with another review author if required to reach agreement but this was not necessary. When information regarding any data were missing, unclear or incomplete, we attempted to contact authors of the original reports to request further details. We entered data in duplicate into Review Manager 5 (RevMan 2014), and checked for accuracy. When information regarding any data was missing, unclear or incomplete, we attempted to contact authors of the original reports to request further details.
Assessment of risk of bias in included studies
Two review authors (EM and DD) independently assessed risk of bias for each included study. We used the Cochrane tool for assessing risk of bias (Table 8 .4.a, Higgins 2011). We had planned to use additional guidance from the Cochrane EPOC group for CBAs and ITS studies (EPOC 2013), but this was not necessary as both included studies were RCTs. We resolved any disagreements by discussion and did not need to consult a third review author. The risk of bias assessors knew the identity of the publication and the author information for each study. We attempted to contact study authors for clarification where the methodology was not clearly described in the study report. We considered selection bias and reporting bias across each study. We planned to report performance bias, detection bias and attrition bias for each outcome (e.g. mortality) or class of outcomes (e.g. subjective outcomes). However, because all outcomes reported in this review required a degree of subjective assessment, we reported risk of bias only by group (class of outcome).
Selection bias: random sequence generation
We assessed the risk that the random sequence generation method used did not produce comparable groups, scoring selection bias thus:
• for RCTs, if the sequence generation process was clearly random (e.g. use of random number table): low risk;
• for RCTs, if the sequence generation process was not specified in the paper and not available from the authors: unclear risk;
• for nRCTs, CBA studies and ITS studies: high risk (but both included studies were RCTs).
Selection bias: allocation concealment
We assessed the risk that the intervention allocation could have been foreseen (was not concealed adequately) in advance of or during recruitment or could have been changed after assignment of participants to intervention groups. We scored selection bias thus:
• if sealed opaque envelopes were used, if randomisation and allocation was performed on all participants or units at the same time after recruitment was completed, if a person outside the study team was responsible for revealing the allocation or if some central allocation process was used (e.g. central telephone contact): low risk;
• any inadequate concealment of allocation (e.g. allocation list available to researchers before recruitment of some participants): high risk;
• if the allocation concealment process was not specified in the paper and not available from the authors: unclear risk;
Performance bias: blinding participants and personnel
Given the nature of many palliative interventions, it is not possible to blind participants and study personnel to the interventions. However, we described the methods used, if any, to blind participants, including family members, and study personnel to the intervention and scored selection bias thus:
• for all outcomes, if participants and study personnel were blinded or if we judged that the lack of blinding was unlikely to impact results: low risk;
• when we considered lack of blinding of participants and study personnel was likely to impact a given outcome: high risk;
• when it was not clear whether lack of blinding of participants and study personnel impacted a particular outcome: unclear risk.
Detection bias: blinding of outcome assessors
We attempted to ascertain whether outcome assessors were blinded to the intervention and scored detection bias thus:
• for all outcomes assessed blindly: low risk;
• for objective outcomes (e.g. mortality), where outcome assessors were not blinded: low risk;
• for subjective outcomes (e.g. pain), where outcome assessors were not blinded: high risk;
• if it was not clear whether outcome assessors were blinded for an outcome that we considered would be impacted by lack of blinding: unclear risk.
Attrition bias: incomplete outcome data
We explored whether dropouts and withdrawals, and reasons why they occurred, were reported, with a particular focus on establishing if missing data were balanced across groups and we scored attrition bias thus:
• if less than 20% of data were missing, and missing data were balanced across groups: low risk;
• if either more than 20% of data were missing or missing data were not balanced across groups: high risk;
• if the percentage of missing data were not clear or it was unclear whether the missing data were equally divided across groups: unclear risk.
Reporting bias
We compared the outcomes reported in the Results section of the study publications with the outcomes listed in the Methods section of the paper reporting the findings and the study protocol (where available) to identify any selective outcome reporting and scored the risk of reporting bias thus:
• if it was clear that all prespecified outcomes and all key expected outcomes were reported: low risk;
• if all the study's prespecified outcomes were not reported or if one or more of the reported primary outcomes were not prespecified: high risk;
• if outcomes of interest were not reported completely or if a key outcome that one would expect to have been reported was not reported: high risk;
• if there was doubt whether the outcomes reported included all outcomes measured: unclear risk.
Other potential sources of bias
We examined the study reports for other potential sources of bias (e.g. the risk of contamination of controls), and scored the risk of bias from other sources thus:
• study appeared to be free of other sources of bias: low risk;
• there was at least one other important risk of bias (e.g. extreme baseline imbalance not adjusted for in analysis or contamination of controls): high risk;
• if there was insufficient information to assess whether another important source of bias existed or if there was not sufficient evidence that an identified problem would introduce bias: unclear risk.
For cluster RCTs, we assessed these additional sources of bias (Section 16.3.2, Cochrane Handbook for Systematic Reviews of Interventions, Higgins 2011):
• recruitment bias (e.g. were people recruited after clusters were randomised or were inclusion/exclusion criteria applied differently in different arms?);
• baseline imbalance between the clusters;
• incorrect analysis -was there evidence of adjustment in analysis for cluster effect?
For each of these sources, we rated the risk of bias as follows:
• if there was clear evidence that no risk of bias was introduced: low risk;
• if there was evidence of a problem and no adjustment had been made in the analysis to counteract it: high risk;
• if insufficient information was available to make a decision on the risk of bias from a specific source: unclear risk.
Summary of risk of bias
All outcomes reported in the 'Summary of findings' table required a degree of subjective assessment. Therefore, we considered that all outcomes were subjective and assessed the overall risk of bias for all outcomes as a group, as follows (guided by Table 8 .7.a in Higgins 2011):
• if most information was from studies at low risk of bias: low risk;
• if the proportion of information from studies at high risk of bias was sufficient to affect the interpretation of the results: high risk;
• if most information was from studies at low or unclear risk of bias: unclear risk.
At an individual study level, we rated studies as high quality when they were at low risk of bias for allocation concealment and incomplete outcome data. Finally, we incorporated the results of the risk of bias assessment into the review through systematic narrative description and commentary. We did not conduct a meta-analysis, therefore, were unable to explore the effect of the risk of bias through a sensitivity analysis based on trial quality, as planned. Additional detail on methods of analysis for 'Risk of bias' assessment that could be used in future updates of this review, should a meta-analysis of data be possible, are available in the protocol for this review (Murphy 2015).
Measures of treatment effect
For dichotomous data, we planned to present results as summary risk ratios (RR) with 95% confidence intervals (CIs). For continuous data, we planned to use the mean difference (MD) with 95% CIs where outcomes were measured using the same scale or in the same way in the included studies. We planned to use change-frombaseline data, or, if these were not available, final value scores. We planned to use the standardised mean difference (SMD) with 95% CIs if studies measured the same outcomes but use different measurement scales (Higgins 2011). Additional details on methods to address unit of analysis issues, assessment of heterogeneity, assessment of reporting bias, data synthesis, and subgroup and sensitivity analysis that could be used in updates of this review, should a meta-analysis of data be possible, are available in the protocol for this review (Murphy 2015).
Dealing with missing data
Where data were missing from published reports, we contacted study authors to request data for included studies. For included studies, we noted the level of attrition, per group, and per outcome or group of outcomes.
Data synthesis
We planned to use Review Manager (RevMan) to conduct statistical analysis; however, the included studies were too disparate in terms of interventions, settings and outcomes to allow pooling of results in a meta-analysis, so we described the results of the trials using a narrative summary.
Summarising and interpreting results
We used the GRADE system to assess the certainty of evidence behind each outcome, taking account of risk of bias in the contributing studies, imprecision of the effect estimate, inconsistency between studies, indirectness of the evidence and possible publication bias (Guyatt 2008). For each comparison, we constructed a 'Summary of findings' table that was an adaptation of that produced from the GRADE Development Tool software (GRADEpro 2014). To identify the seven most important outcomes for inclusion in the 'Summary of findings' table, we conducted a prioritysetting exercise. An online survey listed all the outcomes measured in the included studies and each author on the review team independently ranked the five outcomes (out of the 31 outcomes measured in the included studies) they considered the most important. From this process, we identified the top seven outcomes for inclusion in the 'Summary of findings' table as:
• palliative care plan adopted during an acute hospital admission;
• palliative care plan available on discharge from an acute hospital;
• decisional conflict in family/informal carers;
• discussions on feeding with a physician/nurse/physician assistant;
• palliative care plan developed during hospitalisation;
• decision to forgo cardiopulmonary resuscitation (CPR) in hospital;
• death in an acute hospital. 
R E S U L T S Description of studies
Results of the search
We identified 1648 citations with potential for inclusion from our initial electronic search in January 2015 and five citations from other sources. A second search in February 2016 identified a further 157 citations (see Figure 1) . After removing duplicates, we screened the titles and abstracts of 1535 citations and excluded 1457 citations. We reviewed the full text of the remaining 78 citations for a more detailed evaluation. We contacted authors of 13 studies to clarify methodological queries, 11 authors responded, one of whom re-analysed data for the purposes of this review (Hanson 2011). Of the full-text studies reviewed, two studies, each reported in two citations, met our inclusion criteria and were included in the review: one individually randomised controlled trial (Ahronheim 2000) and one cluster RCT (Hanson 2011). We identified no completed quasi-randomised studies, CBAs or ITS.
Included studies
The individually randomised controlled trial involved 99 participants with advanced dementia (Ahronheim 2000) and the cluster RCT included 256 dyads, where each person with advanced dementia was recruited with a surrogate decision-maker; 90 dyads in the study population met the advanced dementia criteria of this review (Hanson 2011).
Participants and settings
The Ahronheim study included people with advanced dementia, staged as FAST 6d-7f, hospitalised for an acute illness (Ahronheim 2000). It was conducted at one acute hospital in the US. The Hanson study included nursing home residents with advanced dementia, staged as GDS 6 or 7, and feeding problems; each resident was enrolled with a surrogate decision maker, defined as the resident's guardian, Health Care Power of Attorney, or the primary family contact and most likely to be involved in clinical decision making (Hanson 2011). Of the 256 dyads in the study, 90 residents were staged as GDS 7, thus meeting the criteria for inclusion in this systematic review, and the authors re-analysed the data for this subset of participants for the purposes of this review. The study was conducted in 24 nursing homes in the US.
Characteristics of the interventions
The Ahronheim study measured the effectiveness of a palliative care team established at the acute hospital, consisting of a clinical nurse specialist and one or more attending geriatrician(s), who also held academic appointments (Ahronheim 2000). The palliative care team visited each person and discussed their management with the primary healthcare team in the hospital on a daily basis during admission, making recommendations with the goal of enhancing each person's comfort. The palliative care team also discussed participant care with surrogates when possible, in person or by telephone. The control group were treated by the primary care team without the input of the palliative care team. The Hanson study tested whether a decision aid for surrogates of nursing home residents with advanced dementia improved the quality of decision-making about feeding options (Hanson 2011). Surrogates received a structured decision aid providing information about dementia; feeding options, including feeding for comfort near the end of life; and the outcomes, advantages and disadvantages of feeding tubes and assisted oral feeding. The decision aid also discussed the surrogate's role in decision making and the surrogates were encouraged to discuss the decision aid with healthcare providers. Control surrogates received usual care, including any information typically provided by healthcare providers.
Outcome measures
In the Ahronheim study, outcomes reported included the total and the mean number of admissions, the number of deaths in hospital, the existence of a palliative care plan, with a breakdown on the number of decisions recorded to forgo each of seven lifesustaining treatments, details on the use of nine life-sustaining interventions during admissions and details on the use of four procedures (feeding tubes, mechanical ventilation, tracheostomy and CPR) (Ahronheim 2000). The outcomes measured in this study focused on the process of care, rather than on the outcomes for the participant or the family/carer. The primary outcome in the Hanson study was decisional conflict of the surrogate at three months (Hanson 2011), measured using the validated Decisional Conflict Scale (O'Connor 1995). Secondary outcomes included knowledge about dementia and feeding options, frequency of feeding discussions between surrogate and care providers and the use of assisted feeding treatments. The primary outcome in this study focused on the family/carer, the secondary outcomes focused mainly on the process of care. In total, the two studies measured 31 different outcomes and no outcome was measured in both studies.
Excluded studies
We excluded 74 citations at full-text stage: 29 did not describe a palliative intervention, 18 did not meet study design criteria, 19 either did not include participants with advanced dementia or less than 80% of the participants had advanced dementia and results were not available separately for those with advanced dementia, and one study included participants with dementia but the severity of dementia was not staged by a validated functional scale. The Characteristics of excluded studies table lists details of studies excluded at full-text stage. In addition, there were seven citations reporting on six ongoing studies meeting the inclusion criteria for this review; data collection was complete in four studies with analysis underway but results not yet available when this review was drafted (Agar 2015; Boogaard 2013; Einterz 2014; Arcand 2015), and data collection was ongoing in the other two studies (NCT01774799; NCT02211287).
Risk of bias in included studies
For risk of bias assessment (see Characteristics of included studies  table) , we grouped all outcomes reported in each included study into one group, subjective outcomes, as the measurement of all outcomes was open to some subjectivity. In the Ahronheim study, we judged risk of performance bias as high, and we judged the risk of selection bias as unclear. We also considered there was a high risk of contamination bias as intervention and control participants were managed by the same medical team. We judged the risk of detection, attrition and reporting bias as low (Ahronheim 2000).
In the Hanson study, we judged the risk of recruitment bias, performance bias and detection bias as high. We judged the risk of selection bias, reporting bias, attrition bias and other biases as low (Hanson 2011). Figure 2 summarises the risk of bias assessment for both studies. 
Effects of interventions
See: Summary of findings for the main comparison Palliative care team in acute hospital; Summary of findings 2 Structured decision aid on feeding options We did not pool data due to the heterogeneity between the two trials in terms of the interventions, the outcomes and the times at which the outcomes were measured. For the same reasons, we did not perform subgroup or sensitivity analyses. Instead, the results of the two trials are presented separately. Ahronheim 2000 provided data on the impact of a palliative care team in an acute hospital. Because the data were from a single study with a small sample size, event rates were low for some outcomes, and there was a high risk of performance bias and contamination bias, we judged the certainty of evidence behind all effect estimates as very low (downgraded due to very serious risk of bias for all outcomes, and downgraded for either or both of inconsistency and imprecision, depending on the outcome). Drawing on data from one study only (Ahronheim 2000), there was evidence that participants allocated to a palliative care team were more likely to have a palliative care plan developed during hospitalisation than participants in the control group (RR 5.84, 95% CI 1.37 to 25.02; 1 trial, 99 participants; Analysis 1.1). Only two participants, both in the intervention group, had a palliative care plan used during hospitalisation, hence we could not draw conclusions about the effect of the intervention on this outcome. The palliative care plan was usually not available until discharge and availability on discharge was more likely in the intervention group (RR 4.50, 95% CI 1.03 to 19.75; 1 trial, 99 participants; Analysis 1.1). There was no difference in mortality in hospital between participants allocated to the palliative care team and participants receiving usual care (RR 1.06, 95% CI 0.53 to 2.13; 1 trial, 99 participants; Analysis 1.2). There was no difference in the mean number of hospital admissions per participant between the groups (MD 0.04, 95% CI -0.74 to 0.82; Analysis 1.3). Data reported suggest that the intervention had no impact on decisions to forgo CPR in hospital or on discharge. Only a small number of decisions were made to forgo treatments other than CPR. There was little use of mechanical ventilation, tracheostomy or CPR in either group. The study reported that participants in the intervention group were less likely to have intravenous therapy during admission, but there was no impact on the use of other lifesustaining treatments, including systemic antibiotics, daily phlebotomy or the number of new feeding tubes inserted. However, data on decisions to forgo CPR and the use of life-sustaining treatments are reported based on the number of admissions rather than the number of participants, thus the effect sizes are more precise than they should be and therefore are not reported here.
One study reported the effect of a decision aid for surrogate decision-makers of nursing home residents with advanced dementia (Hanson 2011). For the purposes of this review, the authors re-analysed the data for 90 study dyads with advanced dementia staged as GDS 7 (35% of total study population), the participant inclusion criterion for the review. Because the data were drawn from a reanalysis of a small subgroup from a single study and the risk of recruitment, performance and detection biases were high, we judged the certainty of the evidence for all outcomes as very low (downgraded due to very serious risk of bias and serious inconsistency).
In this subset, the intervention surrogate decision-makers had lower total scores on the Decisional Conflict Scale (MD -0.30, 95% CI -0.61 to 0.01; 1 trial, 90 participants; Analysis 2.1) and were more likely than controls to discuss feeding options with a physician, nurse practitioner or physician assistant (RR 1.57, 95% CI 0.93 to 2.64; Analysis 2.2), although in both outcomes the CIs included no difference. A change of 0.3 to 0.4 on the Decisional Conflict Scale is considered a meaningful change (O'Connor 1993). Participants whose surrogate decision-makers received the decision aid intervention were more likely to receive a modified diet (RR 1.19, 95% CI 0.31 to 4.54; 1 trial, 90 participants; Analysis 2.3) and were more likely to be on a specialised dysphagia diet (RR 1.30, 95% CI 1.09 to 1.56; Analysis 2.3). The intervention had no impact on the use of other assisted oral feeding techniques.
No surrogates in either group had made an explicit choice for or against a feeding tube at three months.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Structured decision aid on feeding options Only a subset of the study population m et the review inclusion criteria, so re-analyse of data f rom subset required 31.8 per 100 50.0 per 100 (29.6 to 84.0) * The risk in the intervention group (and its 95% conf idence interval) is based on the assum ed risk in the com parison group and the relative effect of the intervention (and its 95% CI). CI: conf idence interval; RCT: random ised controlled trial; RR: risk ratio.
D I S C U S S I O N Summary of main results
The primary aim of this review was to assess the effect of palliative care interventions in advanced dementia. We included two trials. Although the populations in the two included studies were similar, differences between the interventions and the outcomes measured meant that it was not possible to conduct a meta-analysis, that is, to pool data meaningfully across the two studies. One study assessed the effect of a palliative care team in an acute hospital (Ahronheim 2000), the other study assessed the impact of a decision aid on the quality of decision-making about feeding options by surrogate decision-makers of nursing home residents with advanced dementia (Hanson 2011). The Hanson 2011 study required a reanalysis of the study data to include only data pertaining to a subset of the study population that met the inclusion criteria of this systematic review.
While one study reported that with a palliative care team intervention in acute hospitals, participants in the intervention group were more likely to have a palliative care plan, the numbers were small and the palliative care plan was typically not in place until discharge (Ahronheim 2000). It was also less likely that intravenous therapy was used in participants in the intervention group during hospitalisation but the intervention did not impact the use of any other life-sustaining treatments or procedures.
In the second study, data for the subset of participants meeting the review definition of advanced dementia was reanalysed (Hanson 2011). From the reanalysis of this subset, we found some evidence that a decision aid helps to reduce decisional conflict in surrogates and leads to increased discussions between surrogates and healthcare providers on feeding options, but there was significant uncertainty about both of these results. However, the original study, drawing on data from the full study population, provided stronger evidence that the intervention has a positive impact for both of these outcomes, which gives us more confidence that there is a true effect. The decision aid also resulted in more residents with advanced dementia being on a specialised dysphagia diet.
Overall completeness and applicability of evidence
The number of included studies, the variation in the interventions and settings of the two included studies and the fact that it was not possible to conduct a meta-analysis of data for any outcome provided insufficient evidence to assess the effect of palliative care interventions in advanced dementia. The two included trials give an indication of the range of outcomes that have been measured to date but it is not possible to have a meaningful discussion on outcomes based on only two trials. The definition of advanced dementia for this review led to the exclusion of some quality studies conducted on a more general population of people with dementia, but our definition does retain a focus on the most vulnerable people with dementia. The latter are a particularly important group given their proximity to death and their need for palliative interventions across a range of activities. They are also a vulnerable group given the difficulty of communication that occurs with advanced dementia and of being understood by care providers even when non-verbal communication is attempted. The existing lack of data on optimal palliative care interventions to meet the needs of this special population highlights the importance of research focused on this population, despite the challenges. The fact that there are six ongoing studies at the time of this review indicates an increased interest in this area by researchers and possibly a recognition by ethics committees of the importance of conducting research in vulnerable populations. There are also signs of a growing convergence in the outcomes that are being measured, which means that the results will be more comparable, with potential to conduct a meta-analysis on some outcomes. We had planned to use the Bausewein model domains and dimensions of outcome measures in palliative care to report on the outcomes measured in the included studies and to analyse separately outcomes for the person with advanced dementia, outcomes related to family or carers and outcomes related to quality of care (Bausewein 2011). However, due to the low number of studies included and the diversity in outcomes measured, this was not possible. It is worth noting that one study focused entirely on process of care outcomes (Ahronheim 2000), while the primary outcome in the Hanson 2011 study related to the family and the secondary outcomes in this study focused mainly on process of care outcomes. However, the six ongoing studies suggest that there is a growing focus on outcomes of relevance to the person with advanced dementia, for example, comfort in dying and comfort at end of life, and of relevance to the family/carer, for example, satisfaction with care, measured using the End-of-Life-in Dementia (EOLD) suite of measurement tools (Volicer 2001).
Quality of the evidence
Very little high quality work has been completed exploring palliative care interventions in advanced dementia. This review included only two trials, with 189 people with advanced dementia. A meta-analysis of the data was not possible, due to variations in the interventions, the settings and the outcomes measured. One study had a small sample size and the number of events was very small. The second study required a reanalysis of a subset of the participants in the original study to include only those participants who met the inclusion criteria for this review, resulting in a small sample size that was no longer powered to measure the primary outcome. We downgraded the evidence from both studies by two due to risk of bias and downgraded the evidence because of other factors. Therefore, the certainty of evidence reported in this review is very low.
Potential biases in the review process
This review was conducted as outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011); therefore, the introduction of bias during the review process was minimised. We are confident that the search strategy identified all relevant studies. Some bias may have been introduced by limiting the reanalysis of data in the Hanson 2011 study to a subset of the original study outcomes but the reanalysis was conducted long after study end specifically for this review.
Limitations of this review
The limitations of this work are related to the small number of studies that met the criteria for inclusion in the review. Quite simply, there has been a dearth of work on palliative care interventions for people with advanced dementia. There are many reasons for so few studies, but an important consideration is the relatively low priority given to palliative care for people with advanced dementia, making it difficult to even imagine different forms of interventions, let alone implement and evaluate them. Methodological issues in respect of randomisation and outcome measures may have also inhibited work in this important area. This may now be changing, given the potential publication of six new studies in this area in the near future, making it possible to conduct more complete reviews, including meta-analyses.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
Ahronheim 2000 advised targeting people with advanced dementia before transfer to acute hospital to allow for discussion on goals of care in a less urgent environment. However, there is a growing consensus internationally that palliative care should be provided across the full continuum of care and across a range of conditions Therefore, we should not abandon efforts to introduce a palliative care approach with these people when they are admitted to acute hospitals, if an advance care plan is not already in place.
However, very little high quality work has been completed exploring palliative care interventions in advanced dementia. We found only two included studies for this review, with variation in the interventions and in the settings that made it impossible to conduct a meta-analysis of data for any outcome. Thus, we conclude that there is insufficient evidence to assess the effect of palliative care interventions in advanced dementia. The fact that there are six ongoing studies at time of this review indicates an increased interest in this area by researchers, which is welcome and needed.
Implications for research
The results of the Hanson study suggest that it is worthwhile to further investigate the use of the decision aids among surrogates of people with advanced dementia (Hanson 2011). It is also evident that high-quality studies of many different palliative care interventions in all settings are required to improve palliative care delivered to people with advanced dementia. The Ahronheim study reminds us of the need to include the acute hospital setting (Ahronheim 2000). Because insufficient evidence is currently available, research is required to identify what the nature of these interventions should be.
Palliative care researchers face many challenges, including the vulnerability of the population from which study participants are recruited; the difficulty in assessing the risks and benefits of participating in the research; and issues around consent, emotional distress and randomisation (Krouse 2004). These challenges are exacerbated when the focus is on people with advanced dementia, particularly related to communication, capacity and appropriate outcome measures. Therefore, there is a need to conduct methodological research to develop best practice guidelines for research in this area.
There is also a clear need for the development of a core outcome set for palliative care for people with advanced dementia. Developing a core outcome set will need to take account of the personhood of people with dementia, including holistic measures that incorporate standard measures such as pain and quality of life alongside functioning and capabilities assessment. This will, in turn, require increased collaboration and interdisciplinary work, bringing together not just clinicians from psychiatry, geriatrics and palliative care, but also expertise in pain management, communication (verbal and non-verbal), psychology, social gerontology, health economics and even philosophy.
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C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Ahronheim 2000
Methods Randomised controlled trial, randomisation at the level of the individual, conducted over a 3-year period in 1 acute hospital in New York, US Participants 99 participants with advanced dementia, staged as FAST 6d or greater, hospitalised for an acute illness. 48 in intervention group, 51 in control group Interventions Intervention: a palliative care team was established in the hospital, consisting of an experienced clinical nurse specialist and ≥ 1 attending geriatrician(s), who also held academic appointments. The palliative care team conducted a palliative consultation for each participant, visited the participant and discussed participant management with the primary healthcare team in the hospital on a daily basis. The palliative care team also met with family carers or other surrogates when they were available and attempted to arrange meetings after hours or by telephone The goal of the intervention was to enhance participant comfort. During consultation, options discussed included:
• avoidance of non-palliative procedures • avoidance of mechanical constraints • administration of pain medication for painful manoeuvres, e.g. ulcer debridement
• rehabilitation methods e.g. repositioning, massage
• counselling of surrogates and care providers about participant's rights and surrogates responsibilities as decision makers
• alternate planning, e.g. forgoing life-sustaining treatments, discharge to hospice, discharge with palliative care plans and avoidance of re-hospitalisation. Control: treatment by primary care team without the input of the palliative care team
Outcomes
Number of admissions, length of stay and number of deaths in hospital Number of non-palliative procedures and interventions Decisions to forgo life-sustaining treatments Decision to adopt a palliative care plan, during hospitalisation and on discharge Notes 1 additional participant was randomised but lost to the study (discharged from the hospital within 24 hours of randomisation) and not included in the analysis This study was supported by grants from The Greenwall Foundation and The Kornfeld Foundation
Risk of bias
Bias
Authors' judgement Support for judgement
Random sequence generation (selection bias)
Unclear risk "After this baseline evaluation, patients were randomly assigned to either the intervention or to the control group." No details given on method of randomisation used.
Interventions
Intervention: surrogates received a structured decision aid (printed or audio version) providing information about dementia and feeding options, including feeding for comfort near the end of life, and the outcomes, advantages and disadvantages of feeding tubes or assisted oral feeding. The decision aid also discussed the surrogate's role in decision making. Surrogates reviewed the decision aid during their enrolment interview and received the printed decision aid to take home. 
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